Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study

BACKGROUND: Prolonged-release fampridine (PR-FAM) 10-mg tablet twice daily is the only approved pharmacological treatment for improvement of walking ability in adults with multiple sclerosis (MS). LIBERATE assessed the safety/effectiveness of PR-FAM in the real-world. OBJECTIVES: The aim of this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Castelnovo, Giovanni, Gerlach, Oliver, Freedman, Mark S., Bergmann, Arnfin, Sinay, Vladimiro, Castillo-Triviño, Tamara, Kong, George, Koster, Thijs, Williams, Heather, Gafson, Arie R., Killestein, Joep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408054/
https://www.ncbi.nlm.nih.gov/pubmed/34322853
http://dx.doi.org/10.1007/s40263-021-00840-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408054/
https://www.ncbi.nlm.nih.gov/pubmed/34322853
http://dx.doi.org/10.1007/s40263-021-00840-x

Ejemplares similares